1
|
Chen YL, Chen CY, Lai KH, Chang YC, Hwang TL. Anti-inflammatory and antiviral activities of flavone C-glycosides of Lophatherum gracile for COVID-19. J Funct Foods 2023; 101:105407. [PMID: 36627926 DOI: 10.1016/j.jff.2023.105407] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/28/2022] [Accepted: 01/03/2023] [Indexed: 01/07/2023] Open
Abstract
Lophatherum gracile (L. gracile) has long been used as a functional food and herbal medicine. Previous studies have demonstrated that extracts of L. gracile attenuate inflammatory response and inhibit SARS-CoV-2 replication; however, the underlying active constituents have yet to be identified. This study investigated the bioactive components of L. gracile. Flavone C-glycosides of L. gracile were found to dominate both anti-inflammatory and antiviral effects. A simple chromatography-based method was developed to obtain flavone C-glycoside-enriched extract (FlavoLG) from L. gracile. FlavoLG and its major flavone C-glycoside isoorientin were shown to restrict respiratory bursts and the formation of neutrophil extracellular traps in activated human neutrophils. FlavoLG and isoorientin were also shown to inhibit SARS-CoV-2 pseudovirus infection by interfering with the binding of the SARS-CoV-2 spike on ACE2. These results provide scientific evidence indicating the efficacy of L. gracile as a potential supplement for treating neutrophil-associated COVID-19.
Collapse
Key Words
- ACE2, angiotensin-converting enzyme 2
- CB, cytochalasin B
- COVID-19
- COVID-19, coronavirus disease 2019
- DMSO, dimethyl sulfoxide
- Flavone C-glycosides
- HBSS, Hank’s balanced salt solution
- HPLC, high-performance liquid chromatography
- IC50, half-maximal inhibitory concentration
- LDH, lactate dehydrogenase
- LG, Lophatherum gracile
- Lophatherum gracile
- MRM, multiple reaction monitoring
- NETs, neutrophil extracellular traps
- Neutrophils
- O2•−, superoxide
- RBD, receptor-binding domain
- ROS, reactive oxygen species
- SARS-CoV-2
- SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- UPLC, ultra-performance liquid chromatography
- fMLF, N-formyl-methionyl-leucyl-phenylalanine
Collapse
|
2
|
Mokuda S, Kawanishi N, Kuroshima S, Kono J, Nakayama H, Mieno H, Kawamoto M. Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan. Vaccine X 2022; 11:100173. [PMID: 35692460 DOI: 10.1016/j.jvacx.2022.100173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 05/13/2022] [Accepted: 06/02/2022] [Indexed: 11/25/2022] Open
Abstract
Anti-spike protein antibody concentration was elevated by BNT162b2 vaccination. In a non-epidemic area, two BNT162b2 vaccine doses elicited good antibody responses. The seroconversion rate was 99.7%. Antibody responses to BNT162b2 in Asian females were higher than Asian males.
Background There are a few reports on antibody responses after a two-dose BNT162b2 vaccination in non-epidemic areas. We evaluated this phenomenon. Methods A total of 344 healthcare workers were vaccinated, and the serum anti-receptor-binding domain (RBD) antibody concentrations before and after two weeks following the two-dose BNT162b2 vaccination were measured using electro chemiluminescence immunoassay system. Results Before vaccination, the antibody titers of all participants were less than 0.6 U/mL. After two doses of the BNT162b2 vaccine injection in 342 participants (2 excluded), a high seroconversion rate (99.7%) was observed. The average (±standard deviation) serum anti-RBD antibody titers were 2324 ± 1739 U/mL. Antibody levels in females and males were 2443 ± 1833 U/mL and 1908 ± 1287 U/mL, respectively (p = 0.037). Conclusion In a non-epidemic area, two BNT162b2 doses induced a satisfactory antibody response, and the antibody concentrations in females were higher than in males.
Collapse
|
3
|
Yusuf AP, Zhang JY, Li JQ, Muhammad A, Abubakar MB. Herbal medications and natural products for patients with covid-19 and diabetes mellitus: Potentials and challenges. Phytomed Plus 2022; 2:100280. [PMID: 35463625 PMCID: PMC9014648 DOI: 10.1016/j.phyplu.2022.100280] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 03/25/2022] [Accepted: 04/12/2022] [Indexed: 04/21/2023]
Abstract
BACKGROUND The presence of diabetes mellitus (DM) among COVID-19 patients is associated with increased hospitalization, morbidity, and mortality. Evidence has shown that hyperglycemia potentiates SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection and plays a central role in severe COVID-19 and diabetes comorbidity. In this review, we explore the therapeutic potentials of herbal medications and natural products in the management of COVID-19 and DM comorbidity and the challenges associated with the preexisting or concurrent use of these substances. METHODS Research papers that were published from January 2016 to December 2021 were retrieved from PubMed, ScienceDirect, and Google Scholar databases. Papers reporting clinical evidence of antidiabetic activities and any available evidence of the anti-COVID-19 potential of ten selected natural products were retrieved and analyzed for discussion in this review. RESULTS A total of 548 papers (73 clinical trials on the antidiabetic activities of the selected natural products and 475 research and review articles on their anti-COVID-19 potential) were retrieved from the literature search for further analysis. A total of 517 articles (reviews and less relevant research papers) were excluded. A cumulative sum of thirty-one (31) research papers (20 clinical trials and 10 others) met the criteria and have been discussed in this review. CONCLUSION The findings of this review suggest that phenolic compounds are the most promising phytochemicals in the management of COVID-19 and DM comorbidity. Curcumin and propolis have shown substantial evidence against COVID-19 and DM in humans and are thus, considered the best potential therapeutic options.
Collapse
Key Words
- 8-OHDG, 8-hydroxy-2’-deoxyguanosine
- ACE2
- ACE2, Angiotensin-converting enzyme 2
- ADMA, asymmetric de-methyl-arginine
- ARDS, acute respiratory distress syndrome
- COVID-19
- Comorbidity
- DM, diabetes mellitus
- Diabetes
- FBS, fasting blood sugar
- GLUT-4, glucose transporter-4
- GSK-3β, glycogen synthase kinase-3β
- HDL, high-density lipoprotein
- HOMA, homeostasis model assessment
- Herbal medication
- IAPP, islet amyloid polypeptide
- IFN, interferon
- IFNAR2, interferon-alpha receptor 2
- IL-6, interleukin-6
- LDL, low-density lipoprotein
- MDA, malondialdehyde
- Mpro, main protease
- Natural products
- PLpro, papain-like protease
- PON1, paraoxonase-1
- RBD, receptor-binding domain
- RCT, randomized control trial
- RdRp, RNA-dependent RNA polymerase
- SARS-CoV-2, severe acute respiratory syndrome coronavirus-2
- SFJDC, Shufeng Jiedu Capsule
- T1D, type 1 diabetes
- T2D, type 2 diabetes
- TAC, total antioxidant capacity
- TMPRSS2, transmembrane protease serine 2
- hs-CRP, high-sensitivity C-reactive protein
Collapse
Affiliation(s)
- Abdurrahman Pharmacy Yusuf
- Department of Biochemistry, School of Life Sciences, Federal University of Technology, P.M.B 65, Minna, Niger State, Nigeria
| | - Jian-Ye Zhang
- Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, P.R. China
| | - Jing-Quan Li
- The first Affiliated Hospital, Hainan Medical University, Haikou, P.R. China
| | - Aliyu Muhammad
- Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University Zaria, 810107, Kaduna State, Nigeria
| | - Murtala Bello Abubakar
- Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Nigeria
- Department of Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Usmanu Danfodiyo University, P.M.B. 2254, Sokoto, Nigeria
| |
Collapse
|
4
|
Gomaa AA, Abdel-Wadood YA. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomed Plus 2021; 1:100043. [PMID: 35399823 PMCID: PMC7886629 DOI: 10.1016/j.phyplu.2021.100043] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 02/02/2021] [Accepted: 02/05/2021] [Indexed: 04/28/2023]
Abstract
BACKGROUND Several recent studies have stated that glycyrrhizin and licorice extract are present in most traditional Chinese medicine formulas used against SARS-CoV-2 in China. Significant data are showing that glycyrrhizin and licorice extract have multiple beneficial activities in combating most features of SARS-CoV-2. PURPOSE The aim of current review was to highlight recent progresses in research that showed the evidence of the potential use of glycyrrhizin and licorice extract against COVID-19. METHODOLOGY We have reviewed the information published from 1979 to October 2020. These studies demonstrated the effects , use and safety of glycyrrhizin and icorice extract against viral infections,bacterial infections, inflammatory disorders of lung ( in vitro and in vivo). These studies were collated through online electronic databases research (Academic libraries as PubMed, Scopus, Web of Science and Egyptian Knowledge Bank). RESULTS Pooled effect size of articles provides information about the rationale for using glycyrrhizin and licorice extract to treat COVID-19. Fifty studies demonstrate antiviral activity of glycyrrhizin and licorice extract. The most frequent mechanism of the antiviral activity is due to disrupting viral uptake into the host cells and disrupting the interaction between receptor- binding domain (RBD) of SARS-COV2 and ACE2 in recent articles. Fifty studies indicate that glycyrrhizin and licorice extract have significant antioxidant, anti-inflammatory and immunomodulatory effects. Twenty five studies provide evidence for the protective effect of glycyrrhizin and licorice extract against inflammation-induced acute lung injury and cardiovascular disorders. CONCLUSION The current study showed several evidence regarding the beneficial effects of glycyrrhizin and licorice extract in combating COVID-19. More randomized clinical trials are needed to obtain a precise conclusion.
Collapse
Key Words
- 18β-GA, 18β-glycyrrhetinic acid
- : ACE2, angiotensin-converting enzyme 2
- ALI, acute lung injury
- ARDS, acute Respiratory Distress Syndrome
- Acute lung injury protector
- COVID-19
- COVID-19, Coronavirus disease 2019
- COX-2, cyclooxygenase-2
- DCs, dendritic cells
- Gl, glycyrrhizin
- Glycyrrhizin and licorice extract;Antiviral and antimicrobial, Anti-inflammatory and antioxidant
- HBsAg, hepatitis B surface antigen
- HCV, hepatitis C virus
- HMGB1, high-mobility group box 1
- IL, interleukin
- Immunododulator
- MAPKs, mitogen-activated protein kinases
- MERS, Middle East respiratory syndrome
- MR, mineralocorticoid receptor
- MRSA, Methicillin-resistant Staphylococcus aureus
- NO, nitric oxide
- RBD, receptor-binding domain
- ROS, reactive oxygen species
- S, Spike
- SARS, severe acute respiratory syndrome
- TCM, traditional Chinese medicine
- TLR, toll-like receptor
- TMPRSS2, type 2 transmembrane serine protease
- TNF-α, tumor necrosis factor alpha
- h, hour
- iNOS, inducible nitric oxide synthase
- licorice extract, LE
Collapse
Affiliation(s)
- Adel A Gomaa
- Department of Medical Pharmacology, Faculty of Medicine, Assiut Universitya, Beni-Suif, Egypt
| | | |
Collapse
|
5
|
Suh JS, Kim HS, Kim TJ. Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. Sens Actuators B Chem 2021; 334:129663. [PMID: 33612970 PMCID: PMC7885701 DOI: 10.1016/j.snb.2021.129663] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 12/16/2020] [Accepted: 02/10/2021] [Indexed: 05/05/2023]
Abstract
The global outbreak of coronavirus disease and rapid spread of the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent a significant threat to human health. A key mechanism of human SARS-CoV-2 infection is initiated by the combination of human angiotensin-converting enzyme 2 (hACE2) and the receptor-binding domain (RBD) of the SARS-CoV-2-derived spike glycoprotein. Despite the importance of these protein interactions, there are still insufficient detection methods to observe their activity at the cellular level. Herein, we developed a novel fluorescence resonance energy transfer (FRET)-based hACE2 biosensor to monitor the interaction between hACE2 and SARS-CoV-2 RBD. This biosensor facilitated the visualization of hACE2-RBD activity with high spatiotemporal resolutions at the single-cell level. Further studies revealed that the FRET-based hACE2 biosensors were sensitive to both exogenous and endogenous hACE2 expression, suggesting that they might be safely applied to the early stage of SARS-CoV-2 infection without direct virus use. Therefore, our novel biosensor could potentially help develop drugs that target SARS-CoV-2 by inhibiting hACE2-RBD interaction.
Collapse
Key Words
- ACE2
- Biosensor
- CQ, chloroquine
- FRET
- HCQ, hydroxychloroquine
- Live-cell imaging
- NA, numerical aperture
- RBD, receptor-binding domain
- RBM, receptor-binding motif
- ROI, region of interest
- SARS-CoV-2
- SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- SEM, standard error of the mean
- bg, background
- hACE2, human angiotensin-converting enzyme 2
Collapse
Affiliation(s)
- Jung-Soo Suh
- Department of Integrated Biological Science, Pusan National University, Pusan 46241, Republic of Korea
| | - Heon-Su Kim
- Department of Integrated Biological Science, Pusan National University, Pusan 46241, Republic of Korea
| | - Tae-Jin Kim
- Department of Integrated Biological Science, Pusan National University, Pusan 46241, Republic of Korea
- Department of Biological Sciences, Pusan National University, Pusan 46241, Republic of Korea
- Institute of Systems Biology, Pusan National University, Pusan 46241, Republic of Korea
| |
Collapse
|
6
|
Zhu G, Zhu C, Zhu Y, Sun F. Minireview of progress in the structural study of SARS-CoV-2 proteins. Curr Res Microb Sci 2020; 1:53-61. [PMID: 33236001 PMCID: PMC7323663 DOI: 10.1016/j.crmicr.2020.06.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 06/24/2020] [Accepted: 06/25/2020] [Indexed: 01/18/2023] Open
Abstract
Major progress has been achieved with regard to the understanding of the phylogeny and genomic organization of SARS-CoV-2. This review summarized crucial developments in the elucidation of the structure and function of key SARS-CoV-2 proteins. The molecular details of SARS-CoV-2 infection and replication could improve the effective clinical treatment.
A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization, broke out in China and rapidly developed into a global pandemic, with millions of cases and hundreds of thousands of deaths reported globally. The novel coronavirus, which was designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the etiological agent of COVID-19. On the basis of experience accumulated following previous SARS-CoV and MERS-CoV outbreaks and research, a series of studies have been conducted rapidly, and major progress has been achieved with regard to the understanding of the phylogeny and genomic organization of SARS-CoV-2 in addition its molecular mechanisms of infection and replication. In the present review, we summarized crucial developments in the elucidation of the structure and function of key SARS-CoV-2 proteins, especially the main protease, RNA-dependent RNA polymerase, spike glycoprotein, and nucleocapsid protein. Results of studies on their associated inhibitors and drugs have also been highlighted.
Collapse
Key Words
- 3CLpro, 3C-like protease
- 6-HB, six-helix bundle
- ACE2, angiotensin-converting enzyme 2
- COVID-19
- COVID-19, coronavirus disease 2019
- CatB/L, cysteine proteases-cathepsin B and L
- Drug-screening
- E protein, Envelope protein
- Genome-encoded proteins
- HR1, heptad repeat 1
- HR2, heptad repeat 2
- M protein, Membrane protein
- MERS-CoV, the Middle Eastern respiratory syndrome coronavirus
- Mpro, Main protease
- N protein, Nucleocapsid protein
- NSP, non-structural protein
- ORF, Open reading frame
- PD, peptidase domain
- RBD, receptor-binding domain
- RBM, receptor-binding motif
- RMP, The remdesivir monophosphate
- RdRp, RNA-dependent RNA polymerase
- S protein, Spike glycoprotein
- SARS-CoV, severe acute respiratory syndrome coronavirus
- SARS-CoV-2
- SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- Structure-based screening
- gRNA, genomic RNA
- sgRNA, subgenomic RNA
Collapse
Affiliation(s)
- Guoliang Zhu
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - Chunmei Zhu
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - Yun Zhu
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- Corresponding authors.
| | - Fei Sun
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- Corresponding authors.
| |
Collapse
|